Who Owns Pyxis Oncology Stock?
NASDAQ: PYXSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 11:13 AM ET
Ownership breakdown
- Held by institutions
- 39.54%
- Held by insiders
- 9.47%
- Institutional holders
- 92
- Institutions 39.5%
- Insiders 9.5%
- Public and other 51.0%
Who owns Pyxis Oncology stock?
Institutional investors own about 39.5% of Pyxis Oncology's shares, spread across 92 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 9.47% of PYXS.
The largest institutional holders are GordonMD Global Investments LP (12.02%), Pfizer Inc (8.43%) and Laurion Capital Management, LP (5.88%). Together, the top 10 institutions control 34.7% of shares outstanding. In their latest filings, 5 of the top 10 institutions increased their PYXS positions and 4 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of PYXS
| Institution | Shares | % Held | Change |
|---|---|---|---|
| GordonMD Global Investments LP | 10.02M | 12.02% | +143.2% |
| Pfizer Inc | 7.03M | 8.43% | 0.0% |
| Laurion Capital Management, LP | 4.90M | 5.88% | -1.9% |
| Vanguard Capital Management LLC | 2.08M | 2.49% | +2.1% |
| Atle Fund Management AB | 966.46K | 1.16% | +390.5% |
| Blackrock Inc. | 867.93K | 1.04% | +10.0% |
| Palo Alto Investors Lp | 864.28K | 1.04% | -14.5% |
| Marshall Wace LLP | 830.54K | 1.00% | +134.3% |
| Renaissance Technologies, LLC | 772.23K | 0.93% | -13.1% |
| Geode Capital Management, LLC | 591.85K | 0.71% | -1.1% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of PYXS
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.42M | 1.71% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 558.77K | 0.67% |
| iShares Trust-iShares Biotechnology ETF | 465.05K | 0.56% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 259.79K | 0.31% |
| iShares Trust-iShares Micro-Cap ETF | 165.47K | 0.20% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 90.20K | 0.11% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 78.71K | 0.09% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 39.89K | 0.05% |
| VANGUARD VALLEY FORGE FUNDS-Vanguard Balanced Index Fund | 26.87K | 0.03% |
| VANGUARD Inst. INDEX Fd.S-Vanguard Inst. Total Stock Market Index Fd. | 26.65K | 0.03% |
Frequently asked questions
Who is the largest shareholder of Pyxis Oncology?
GordonMD Global Investments LP is the largest institutional shareholder of PYXS, owning 12.02% of shares outstanding (10.02M shares) as of its latest 13F filing.
What percentage of Pyxis Oncology is owned by institutions?
Institutions own about 39.5% of PYXS shares and 43.7% of the public float.
How much of Pyxis Oncology do insiders own?
Insiders, such as officers and directors, own about 9.47% of PYXS shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.